NAV

Medrogestone

Identification

Summary

Medrogestone is a progestin used as an adjunct to control secondary amenorrhea and dysfunctional bleeding in adolescent and adult females, and treat endometrial shedding in menopausal women.

Generic Name
Medrogestone
DrugBank Accession Number
DB09124
Background

Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. It was conceived as an alternative for an orally effective contraceptive option.1 It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.7 It was never approved by the FDA.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
3D
Similar Structures
Weight
Average: 340.507
Monoisotopic: 340.24023027
Chemical Formula
C23H32O2
Synonyms
  • Medrogestone
External IDs
  • AY 62022
  • AY-13615
  • AY-13615S
  • AY-62022
  • NSC-123018
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Medrogestone is indicated as adjunct to treat endometial shedding in menopausal women, to treat secondary amenorrhea, to induce menses and to treat dysfunctional uterine bleeding in adult and adolescent women.2

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Medrogestone was created as a more potent and orally active option of progesterone. In pre-clinical trials, medrogestone was proven to have four times more progestational activity than progesterone with a similar duration effect than the one found for 17-hydroxyprogesterone. Medrogestone was also able to maintain pregnancy and prevented ovulation in ovariectomized rats. Administration of medrogestone, alone or with premarin, prevented pregnancy, as well as it suppressed ovarian weight increase by nearly 100% of the tested individuals. Medrogestone does not produce any androgenic effect but it presented a marked anti-androgenic effect. It did not present an oestrogenic effect, nor changes in organ weight or histological appearance in adrenal glands or thymus and it does not present any anti-inflammatory effects.1

Mechanism of action

Medrogestone is a progestogen, thus its action is done under the same profile. These type of molecules are steroid hormones that bind and activate the progesterone receptor.3 Its action may involve the suppression of gonadotropic hormones from the anterior portion of the pituitary gland and secondary suppression of testosterone. Medrogestone presents structural similarities to testosterone which allows it to compete for the androgen-receptor-protein receptor sites in prostatic cells.4 Administration of medrogestone diminishes the response to endogenous hormones in tumor cells due to a reduction in hormone steroid receptors; this effect will translate into cytotoxic or antiproliferative effects.2

TargetActionsOrganism
AProgesterone receptor
ligand
Humans
Absorption

When administered, medrogestone presents a very rapid gastrointestinal absorption with a bioavailability of 100%. The maximum serum concentration of medrogestone is 10-15 ng/ml.5

Volume of distribution

Not Available

Protein binding

Medrogestone, as presented for all progestogens, is highly bound to plasma proteins. It is mainly bound to albumin but it also binds to other plasma proteins like sex hormone binding globulin or corticosteroid-binding globulin.5 The pharmacokinetics of medrogestone will depend on the degree of plasma protein bindind which makes this characteristic the main regulator of the tissue availability of medrogestone.6

Metabolism

The non-protein bound fraction of medrogestoneis available for metabolism.6 The main route in the metabolism of medrogestone is hydroxylation.5

Route of elimination

The elimination time of medrogestone is of 36 hours.5

Half-life

The half-life of medrogestone is reported to be of 4 hours.5

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

There were reports of increased urinary flow rates and total micturition volumes as well as sexual dysfunction and hyperglycemia.4

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbametapirThe serum concentration of Medrogestone can be increased when it is combined with Abametapir.
AbciximabMedrogestone may decrease the anticoagulant activities of Abciximab.
AcenocoumarolMedrogestone may decrease the anticoagulant activities of Acenocoumarol.
AlteplaseMedrogestone may decrease the anticoagulant activities of Alteplase.
AmiodaroneThe metabolism of Medrogestone can be decreased when combined with Amiodarone.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Colprone Tab 5mgTablet5 mg / tabOralAyerst Laboratories1969-12-311997-08-15Canada flag
Colprone Tab 5mgTablet5 mg / tabOralWyeth Ayerst Canada Inc.1996-10-252001-08-30Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
PRESOMEN 28 COMP 0.3/5MGMedrogestone (5 mg) + Conjugated estrogens (0.3 mg)Tablet, coatedOral2017-01-012021-10-15Germany flag
PRESOMEN 28 COMP 0.3/5MGMedrogestone (5 mg) + Conjugated estrogens (0.3 mg)Tablet, coatedOral2017-01-012021-08-01Germany flag
PRESOMEN 28 COMP 0.6/5MGMedrogestone (5 mg) + Conjugated estrogens (0.6 mg)Tablet, coatedOral2017-01-012021-08-01Germany flag
PRESOMEN 28 COMP 0.6/5MGMedrogestone (5 mg) + Conjugated estrogens (0.6 mg)Tablet, coatedOral2017-01-012022-01-15Germany flag
PRESOMEN CONTI 0.6MG/2MGMedrogestone (2 mg) + Conjugated estrogens (0.6 mg)Tablet, coatedOral2017-01-012021-11-01Germany flag

Categories

ATC Codes
G03DB03 — MedrogestoneG03FB07 — Medrogestone and estrogen
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxosteroids / Cyclohexenones / Organic oxides / Hydrocarbon derivatives
Substituents
20-oxosteroid / 3-oxosteroid / Aliphatic homopolycyclic compound / Carbonyl group / Cyclic ketone / Cyclohexenone / Hydrocarbon derivative / Ketone / Organic oxide / Organic oxygen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
077DN93G5B
CAS number
977-79-7
InChI Key
HCFSGRMEEXUOSS-JXEXPEPMSA-N
InChI
InChI=1S/C23H32O2/c1-14-12-17-18(21(3)9-6-16(25)13-20(14)21)7-11-23(5)19(17)8-10-22(23,4)15(2)24/h12-13,17-19H,6-11H2,1-5H3/t17-,18+,19+,21-,22-,23+/m1/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-14-acetyl-2,8,14,15-tetramethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8-dien-5-one
SMILES
[H][C@@]12CC[C@](C)(C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=C(C)C2=CC(=O)CC[C@]12C

References

General References
  1. Revesz C, Chappel CI: Biological activity of medrogestone: a new orally active progestin. J Reprod Fertil. 1966 Dec;12(3):473-87. [Article]
  2. Jones & Bartlett (2016). 2016 Nurse's drug handbook (15th ed., pp. 985). Jones and Bartlett Publishers Inc..
  3. Clark M., Harvey R., Finkel R., Rey J. and Whalen K. (2011). Pharmacology (5th ed.). Lippincott Williams & Wilkins.
  4. Hinman F. (1983). Benign prostatic hypertrophy (1st ed.). Kingsport Press.
  5. Lobo R., Crosignani P., Paoletti R. and Bruschi F. (2002). Women's health and menopause (1st ed.). Kluwer Academic Publishers.
  6. Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.
  7. Health Canada [Link]
PubChem Compound
9949848
PubChem Substance
310265040
ChemSpider
8125459
RxNav
6690
ChEBI
135446
ChEMBL
CHEMBL2106825
ZINC
ZINC000004216820
Wikipedia
Medrogestone
MSDS
Download (78.8 KB)

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
TabletOral5 MG
TabletOral5 mg / tab
Tablet, coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)144-146ºC'MSDS'
boiling point (°C)467.17ºC at 760 mmHg'MSDS'
water solubility5.34e-06 mol/L'MSDS'
logP4.45'MSDS'
Predicted Properties
PropertyValueSource
Water Solubility0.00404 mg/mLALOGPS
logP4.35ALOGPS
logP4.59Chemaxon
logS-4.9ALOGPS
pKa (Strongest Acidic)19.18Chemaxon
pKa (Strongest Basic)-4.9Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area34.14 Å2Chemaxon
Rotatable Bond Count1Chemaxon
Refractivity102.6 m3·mol-1Chemaxon
Polarizability40.37 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0049000000-5b474a2097bd16592611
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0009000000-32581930e5f56478939a
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0019000000-6c406a1f38cbe388e61f
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0076-0895000000-2ff808949c5644fd2f6f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0076-5029000000-b2d8723fa0df58522a53
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-000b-0920000000-b171b3578e08bf9c53bd
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-185.36458
predicted
DeepCCS 1.0 (2019)
[M+H]+187.26
predicted
DeepCCS 1.0 (2019)
[M+Na]+193.25642
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Progesterone receptor
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Ligand
General Function
Zinc ion binding
Specific Function
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
Gene Name
PGR
Uniprot ID
P06401
Uniprot Name
Progesterone receptor
Molecular Weight
98979.96 Da
References
  1. Clark M., Harvey R., Finkel R., Rey J. and Whalen K. (2011). Pharmacology (5th ed.). Lippincott Williams & Wilkins.

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Binkowska M, Woron J: Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43. doi: 10.5114/pm.2015.52154. Epub 2015 Jun 22. [Article]

Carriers

Details1. Serum albumin
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Lobo R., Crosignani P., Paoletti R. and Bruschi F. (2002). Women's health and menopause (1st ed.). Kluwer Academic Publishers.
Details2. Sex hormone-binding globulin
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Androgen binding
Specific Function
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone...
Gene Name
SHBG
Uniprot ID
P04278
Uniprot Name
Sex hormone-binding globulin
Molecular Weight
43778.755 Da
References
  1. Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.
Details3. Corticosteroid-binding globulin
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Carp H. (2015). Progestogens in obstetrics and gynecology.. Springer.

Drug created at September 23, 2015 16:20 / Updated at June 16, 2021 12:31